Document is current
Any future updates will be listed below
-
Authors
Ingram, Donald K.
Roth, George S.
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 5 November 2020
First Online: 12 November 2020
Compliance with ethical standards
:
: Donald K. Ingram is a stockholder and serves as Chief Scientific Officer for GeroScience and Prolongevity Technologies. Both companies are directed toward developing glycolytic inhibitors as an anti-aging intervention. George S. Roth is a stockholder and serves as Chief Executive Officer for GeroScience and Prolongevity Technologies. Both companies are directed toward developing glycolytic inhibitors as an anti-aging intervention.
